(Press-News.org) Boston, Mass. -- Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches.
Now, investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. The team, led by Beth Israel Deaconess Medical Center's (BIDMC) Rupal Bhatt, MD, PhD, and University College Cork, Ireland's Thomas Walther, PhD, published their findings in the journal Science Translational Medicine.
"Our team reported that ACE2 is a new protective molecule for RCC, and building on this finding, we show that angiotensin-(1-7), a small peptide generated by ACE2, can be used to control tumor growth in preclinical models," said co-corresponding Bhatt, a medical oncologist at BIDMC and associate professor of medicine at Harvard Medical School. "Our findings suggest that angiotensin-(1-7) could be developed in clinical trials as a promising therapeutic option in patients with RCC in combination with current standard of care treatments and has a strong potential to improve overall survival."
ACE2 is an enzyme that belongs to the renin-angiotensin system (RAS) and antagonizes the classical angiotensin II/AT1 receptor pathway. Interestingly, it is also the receptor for the SARS-CoV2 spike protein, and its downregulation by the virus leads to the often deadly progression of acute respiratory distress syndrome in COVID-19 patients.
Bhatt, Walther and colleagues show that higher ACE2 expression correlates with better overall survival in patients with RCC. They also demonstrated that VEGF receptor inhibitors such as sunitinib and axitinib down-regulate ACE2 expression in tumor cells in culture and in tumors in mouse models of RCC. Using novel and innovative methods and techniques, the authors generated multiple lines of evidence that this ACE2 down-regulation can be causative for the resistance to VEGF pathway inhibition, the inevitable consequence of this approved used class of drugs.
The authors also report that angiotensin-(1-7) is the likely mediator of this effect. The authors also showed that triple therapy of VEGF pathway inhibitors and anti-PD-L1 with angiotensin-(1-7) is superior to the actual standard treatment with VEGR and PD-1 pathway inhibition.
"Our work shows that angiotensin-(1-7) could provide a promising therapeutic option in patients with RCC in combination with VEGF-pathway inhibitors," said co-corresponding author Walther, Professor in Pharmacology at the University College Cork. "Resistance to VEGF-pathway inhibitors is a general problem in cancer treatment and therefore our findings have broader implications for VEGF-pathway inhibitor therapies that beyond RCC could be extended to other types of cancers."
INFORMATION:
Co-authors included Prateek Khanna, Chun-Hau Chen, Ruchi Saxena, Manoj Bhasin, Seema Amin and Patrick Neset Joslin of BIDMC, Hong Jie Soh, Maura Naughton, Andrew Moore and Carol O'Callaghan of the University College Cork, Ziad Bakouny, Paul Catalano, Rana McKay, Toni K. Choueiri and Sabina Signoretti of Dana-Farber Cancer Institute.
This work was supported by grants from the National Institutes of Health Funding (R01 CA196996, R01 NS105910-01, and P50 CA101942-12) and Science Foundation Ireland (1R01HL150145-01).
Together with Kuebler, Walther is a co-inventor of the patent "Use of an Ang-(1-7) receptor agonist in acute lung injury" (application no. 08016142.5-2107). Walther is also a scientific advisor of Constant Pharmaceuticals LTD (Boston, USA). A patent by Bhatt and BIDMC was filed on 16 April 2017 for the "Combination therapy for cancer" outlining combination of VEGFR inhibition with angiotensin pathway molecules. Bhatt also has a patent pending for the use of Ang-(1-7) and VEGFR-TKI therapy in RCC.
For a full list of support and disclosures, please refer to the manuscript.
Catnip and silver vine have been known as cat attractant plants. Cat lovers use dry leaves of these plants and toys stuffed with the leaves to give joy to their pet cats. But how does this work? What is the biological significance of the responsive behavior? A research group at Iwate University, Nagoya University, Kyoto University, and University of Liverpool found that the behavior had more practical reasons than getting euphoria.
"The first appearance of silver vine ("Matatabi" in Japanese) as a cat attractant in literature in Japan dates back to more than 300 years ago. A folklore Ukiyo-e drawn in 1859 shows a group of mice trying to tempt some ...
Scientists at the University of Southampton and University of Edinburgh have developed a flexible underwater robot that can propel itself through water in the same style as nature's most efficient swimmer - the Aurelia aurita jellyfish.
The findings, published in Science Robotics, demonstrate that the new underwater robot can swim as quickly and efficiently as the squid and jellyfish which inspired its design, potentially unlocking new possibilities for underwater exploration with its lightweight design and soft exterior.
Co-author Dr Francesco Giorgio-Serchi, ...
Researchers at the National Institutes of Health have discovered a new genetic disorder characterized by developmental delays and malformations of the brain, heart and facial features. Named linkage-specific-deubiquitylation-deficiency-induced embryonic defects syndrome (LINKED), it is caused by a mutated version of the OTUD5 gene, which interferes with key molecular steps in embryo development. The findings indicate that the newly identified pathway may be essential for human development and may also underlie other disorders that are present at birth. The information will help scientists better understand such diseases--both common ...
Researchers have developed an automated method that can track the development of harmful clumps of TAU protein related to Alzheimer's disease in the brain, according to work involving 443 individuals. The method revealed that TAU primarily emerged in an area of the brain called the rhinal cortex before spreading elsewhere, suggesting that targeting TAU here could potentially slow the progression of Alzheimer's disease. The buildup of toxic amyloid-beta and TAU proteins is responsible for many of the symptoms and damage to neurons seen in Alzheimer's disease. However, current therapies have shown reduced efficacy, at least in part because the therapies were administered long ...
A new Northwestern University study reaffirms the importance of getting a good night's sleep.
By examining fruit flies' brain activity and behavior, the researchers found that deep sleep has an ancient, restorative power to clear waste from the brain. This waste potentially includes toxic proteins that may lead to neurodegenerative disease.
"Waste clearance could be important, in general, for maintaining brain health or for preventing neurogenerative disease," said Dr. Ravi Allada, senior author of the study. "Waste clearance may occur during wake and sleep but is substantially enhanced during deep sleep."
The ...
Rubbing against catnip and silver vine transfers plant chemicals that researchers have now shown protect cats from mosquitoes. The results also demonstrate that engaging with nepetalactol, which the study identified as the most potent of many intoxicating iridoid compounds found in silver vine, activates the opioid reward system in both domesticated felines and big jungle cats. While nepetalactol had been previously identified, these studies directly illuminate its extremely potent effect on cats. And by revealing the biological significance of well-known feline behaviors, ...
Methamphetamine overdose deaths surged in an eight-year period in the United States, according to a study published today in JAMA Psychiatry. The analysis revealed rapid rises across all racial and ethnic groups, but American Indians and Alaska Natives had the highest death rates overall. The research was conducted at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
Deaths involving methamphetamines more than quadrupled among non-Hispanic American Indians and Alaska Natives from 2011-2018 (from 4.5 to 20.9 per 100,000 people) overall, with ...
BOSTON -- While deaths related to heart disease have declined among older people, studies suggest that death rates among younger patients have remained stagnant or increased slightly. To understand what factors put younger individuals at higher risk of premature coronary heart disease (CHD), researchers from Brigham and Women's Hospital and the Mayo Clinic analyzed more than 50 risk factors in 28,024 women who participated in the decades-long Women's Health Study. Notably, women under 55 with type-2 diabetes had a tenfold greater risk of having CHD over the next two decades, with lipoprotein insulin resistance ...
Over the past 20 years, scientists have been developing metamaterials, or materials that don't occur naturally and whose mechanical properties result from their designed structure rather than their chemical composition. They allow researchers to create materials with specific properties and shapes. Metamaterials are still not widely used in everyday objects, but that could soon change. Tian Chen, a post-doc at two EPFL labs - the Flexible Structures Laboratory, headed by Pedro Reis, and the Geometric Computing Laboratory, headed by Mark Pauly - has taken metamaterials one step further, ...
What The Study Did: This observational study examined how COVID-19-related government-mandated closures and restrictions were associated with changes in mobility and the spread of COVID-19 in Nigeria.
Author: Daniel O. Erim, M.D., Ph.D., M.Sc., of Parexel International in Durham, North Carolina, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2020.32101)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# ...
